From targeted panels to whole genome sequencing, physicians and oncologists are ordering a growing number of genetic tests for an expanding menu of applications.
To fulfill the timeliness of genomics-guided precision medicine, clinical testing labs are challenged to rapidly analyze and interpret these genetic tests with the latest scientific evidence, drug approvals and treatment guidelines in an efficient, yet thorough, manner. QIAGEN Clinical Insights (QCI®) offers expert-curated knowledge, software and services to support clinicians in next-generation sequencing (NGS) data analysis and interpretation for accelerated decisions and better patient outcomes.
For clinical testing labs performing variant interpretation and reporting in-house, QCI Interpret is a clinical decision support software enabling faster test turnaround times and higher confidence reporting for any assay on your sequencing platform.
For molecular diagnostics testing labs outsourcing somatic variant interpretation, QCI Precision Insights is a clinical decision support service powered by N-of-One that provides actionable, patient-specific clinical interpretation using the latest scientific evidence.
On Wednesday, November 6, at 2:00 PM, QIAGEN is hosting a full day of talks from industry leaders and customers. Hear from Dr. Ravindra Kolhe, Medical Director of Cytogenetics Laboratory at Augusta University Medical Center, and Dr. Beate Litzenburger, QIAGEN’s Global Product Manager of QCI, as they discuss how clinicians who are reporting on tumor mutational burden (TMB) and microsatellite instability (MSI) status can leverage either QCI Interpret or QCI Precision Insights for faster turnaround times and simplified interpretation.
QCI Interpret is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels, and clinical-trials. Based on this evaluation, the software proposes a classification to aid in the interpretation of observed variants. The software is NOT intended as a primary diagnostic tool by physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national, and local clinical laboratory regulations and other specific accreditations requirements.